IN8bio, Inc.
INAB
$1.87
-$0.04-2.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.65M | 9.90M | 10.76M | 11.58M | 12.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.86M | 21.05M | 23.13M | 26.61M | 29.60M |
| Operating Income | -19.86M | -21.05M | -23.13M | -26.61M | -29.60M |
| Income Before Tax | -19.44M | -20.66M | -23.89M | -27.43M | -30.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -19.44 | -20.66 | -23.89 | -27.43 | -30.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -19.44M | -20.66M | -23.89M | -27.43M | -30.44M |
| EBIT | -19.86M | -21.05M | -23.13M | -26.61M | -29.60M |
| EBITDA | -18.09M | -19.16M | -21.12M | -24.73M | -27.76M |
| EPS Basic | -4.78 | -6.45 | -10.10 | -14.37 | -18.31 |
| Normalized Basic EPS | -2.99 | -4.03 | -5.89 | -8.56 | -11.02 |
| EPS Diluted | -4.78 | -6.45 | -10.10 | -14.37 | -18.31 |
| Normalized Diluted EPS | -2.99 | -4.03 | -5.89 | -8.56 | -11.02 |
| Average Basic Shares Outstanding | 18.54M | 14.03M | 11.07M | 8.52M | 7.18M |
| Average Diluted Shares Outstanding | 18.54M | 14.03M | 11.07M | 8.52M | 7.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |